This inventor holds 2 USPTO granted patents and 8 published patent applications and 1 EPO patent. Top assignee: Avalo Therapeutics, Inc.. Active years: 2023-2025.
Location History:
- Havertown, PA (US) (2023)
- Haverford, PA (US) (2023)
Company Filing History:
Years Active: 2023-2025
Title: The Innovations of Garry A. Neil in ADHD Research
Introduction
Garry A. Neil is an esteemed inventor and researcher based in Haverford, Pennsylvania, who has made significant contributions to the field of medical science. With a focus on innovative methods for diagnosing and treating Attention Deficit Hyperactivity Disorder (ADHD), his work has the potential to change the way this condition is understood and managed.
Latest Patents
Garry A. Neil holds a notable patent titled "Methods of diagnosing and treating ADHD in biomarker positive subjects." This patent relates to the identification of a specific subset of mGluR network gene copy number variations (CNVs) that are predictive of treatment efficacy with fasoracetam. Additionally, it addresses the identification of an mGluR network gene CNV that predicts an increased likelihood of having ADHD and certain associated symptoms. This innovative approach is a significant advancement in personalized medicine for ADHD treatment.
Career Highlights
Garry A. Neil currently works at The Children's Hospital of Philadelphia, a renowned institution dedicated to pediatric care and research. His role involves pioneering research that integrates genetic insights into ADHD, aiming to improve diagnostic precision and treatment strategies. His groundbreaking work has paved the way for enhanced understanding and applications in the field.
Collaborations
In his career, Garry has collaborated with esteemed colleagues such as Liza Squires and Hakon Hakonarson. These partnerships reflect a commitment to advancing scientific knowledge and continuing the exploration of genetic markers that influence ADHD. Working alongside skilled professionals enhances the impact of their research and enriches the scientific community.
Conclusion
Garry A. Neil’s innovative contributions to ADHD research exemplify the importance of integrating genetic insights into healthcare. Through his patent and collaborative efforts at The Children's Hospital of Philadelphia, he is shaping the future of ADHD diagnosis and treatment. His work not only aids in understanding this prevalent condition but also offers hope for more effective therapeutic strategies for those affected.